Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 317

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 317
---
 • Profusa’s post -closing condition.The NorthView Board also considered factors such as Profusa’s outlook, financial plan and debt structure, taking into consideration the fact that, after consummation of the Merger, Profusa will have approximately $15 million of cash on its balance sheet (which condition was subsequently waived on the condition that the combined company is able to meet Nasdaq’s minimum listing requirements), positioning it to execute its plan to: (i)Ramp up operations to produce sensors, readers and launch its AI platform (ii)Complete pivotal studies and obtain approval of the Lumee Oxygen product in the US. File for FDA approval of the Lumee CGM product. (iii)Build commercial resources and operational capabilities (iv)Commercialize the Lumee Oxygen product and prepare for and execute commercial launch of the Lumee CGM product. • Purchase price paid by the Company to Profusa is fair to the Company from a financial point of view.Based on Marshall & Stevens’ fair value analysis, Management analysis and legal due diligence, the NorthView Board determined that the value of the consideration to be deliver by the Company to Profusa shareholders is fair to the Company from a financial point of view. Marshall & Stevens specifically provided the opinion that the value of the consideration to be provided by the Company to Profusa shareholders in the Merger, as provided in the Merger Agreement, is fair to the Company from a financial point of view. 160 The NorthView Board also considered a variety of uncertainties, risks and other potentially negative factors relating to the Merger including, but not limited to, the following: redemptions, complexities related to the stockholder vote, litigation and threats of litigation and broader macroeconomic risks, including Profusa’s status as an early stage company without an operating history, the competitive landscape, the uncertainties of FDA approval and the execution risk that could create difficulties for Profusa in effectively managing its commercialization and distribution of its products and, subsequently, managing its growth and expanding its operations. Specifically, the NorthView Board considered the following issues and risks: • Risk that the benefits described above may not be achieved.The risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe. • Risk of the liquidation of NorthView.The risks and costs to NorthView if the Merger is not completed, including the risk of diverting management’s focus and resources from other business combination opportunities, which could result in NorthView being unable to effect a business combination in